A Study of SH009 Injection in Patients With Advanced Solid Tumors.
An Open, Multicenter, Phase I Clinical Study on the Safety, Efficacy, and Pharmacokinetics of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
150 participants
May 16, 2025
INTERVENTIONAL
Conditions
Summary
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The dosage of SH009 is 40 mg/kg QW with a treatment cycle of 28 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07390838